전체메뉴

Journal of Pharmacopuncture

Article Search

JoP

Best Practice

Compliance of Journal of Pharmacopuncture to the Principles of transparency and best practice in scholarly publishing
(joint statement by COPE, DOAJ, WAME, and OASPA;- http://doaj.org/bestpractice)

Enacted March 19, 2020

  • 1. Website:
    • i. The URL address of official journal web site: https://www.journal-jop.org
      ii. ‘Aims & Scope’ statement:

      Aims
      The Journal of Pharmacopuncture is an international, peer-reviewed open-access journal published in English by the Korean Pharmacopuncture Institute (KPI). The journal has provided high-quality papers quarterly since it was launched in 1997. Its ISSN was changed in September 2010
      from 1226-4849 to 2093-6966 when its title was changed from Daehanyakchimhakhweiji to the Journal of Pharmacopuncture. The journal aims to publish evidence-based, scientific research papers in the multidisciplinary field of traditional and modern medicine through a strict review process by a panel of experts. As an international journal, the Journal of Pharmacopuncture also aims to present major advances and new developments contributing to the advancement of complementary and alternative medicine, with a special focus on pharmacology, acupuncture and a combination of pharmacology and acupuncture. The journal is dedicated to disseminating current data and ideas and fostering debate on issues related to complementary and alternative medicine and to providing better information to both the general public and experts. In addition, the journal requires high standards of research ethics to maintain the integrity of science. The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.' For submission, see the details at http://www.journal-jop.org

      Scope
      The Journal of Pharmacopuncture covers a wide range of basic and clinical science research relevant to all aspects of the biotechnology of integrated approaches using both pharmacology and acupuncture therapeutics, including research involving pharmacology, acupuncture studies and pharmacopuncture studies. The subjects are mainly divided into three categories: pharmacology (applied phytomedicine, plant sciences, pharmacology, toxicology, medicinal plants, traditional medicines, herbal medicine, Sasang constitutional medicine, herbal formulae, foods, agricultural technologies, naturopathy, etc.), acupuncture (acupressure, electroacupuncture, laser acupuncture, moxibustion, cupping, etc.), and pharmacopuncture (aqua-acupuncture, meridian pharmacopuncture, eight-principles pharmacopuncture, animal-based pharmacopuncture, mountain ginseng pharmacopuncture, bee venom therapy, needle embedding therapy, implant therapy, etc.). Other categories include chuna treatment, veterinary acupuncture and related animal studies, alternative medicines for treating cancer and cancer-related symptoms, etc. Broader topical coverage on the effects of acupuncture, the medical plants used in traditional and alternative medicine, pharmacological action and other related modalities, such as anthroposophy, homeopathy, ayurveda, bioelectromagnetic therapy, chiropractic, neural therapy and meditation, can be considered to be within the journal's scope if based on acupoints and meridians.
      iii. Readership: JoP is primarily for medical researchers and clinicians of acupuncture, traditional medicine, integrative medicine, complementary and alternative medicine, and other personnel who work in the field of medicine. Its readership can be expanded to other positions related to subjects described in aims and scope.
      iv. Authorship criteria: The authorship should be given according to 1) making substantial contribution to the conception and design of the study, or acquisition, interpretation and analysis of data; 2) drafting the article or revising it critically for the important intellectual content; and 3) final approval of the version to be published. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
      v. Duplicate submission and redundant publication: Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by Similarity Check upon arrival. If plagiarism or duplicate publication is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.
      vi. pISSN: 2093-6966 eISSN: 2234-6856
  • 2. Name of journal
    • The official title of the journal is 'Journal of Pharmacopuncture', and the abbreviated title is 'J. Pharmacopunct.'
  • 3. Peer review process
    • We adopt the double-blind peer review.

      Reviewers are assigned to a submitted paper for peer review.

      Anything indicating identification of authors is removed from the papers assigned for review. The invited reviewers should give a review of the assigned paper within 15 days after agreeing to do review.

      Reviewers classify the paper as accepted in present form, minor revision (accepted after modest revisions), major revision (reconsidered for acceptance after major changes), and rejected at this stage.

      When the paper is evaluated as minor revision (accepted after modest revisions), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When a paper is evaluated as major revision (reconsidered for acceptance after major change), the reviewers should specify where should be made corrections. Revised papers are put under a second review by the reviewers or the Editorial Board members to determine whether they are acceptable in revised form.

      When the paper is rejected at this stage, the reviewers should cite specific reasons as to how the decision was reached.

      Review results will be sent to the authors once the required reviews are completed.

      Reviewers should post review results on the website of the Journal of Pharmacopuncture. Emails from reviewers and authors are considered as digital signatures.
  • 4. Ownership and management
  • 5. Governing body
    • The governing body is the journal’s editorial board.
  • 6. Editorial team and contact information
    • i. Editorial team is available from the Editorial Board page at the front part of the journal.
      ii. Contact information
      Seokhyun Kang
      JoP Editorial office
      4F AKOM Building, 91, Heojun-ro, Gangseo-gu, Seoul 07525, Korea, Tel: +82-2-2658-9051, Fax: +82-2-2658-9136, E-mail: kpi-jpharmaco@naver.com
  • 7. Copyright and licensing
    • i. Copyright policy: Published manuscripts become the permanent property of the Korean Pharmacopuncture Institute and may not be published elsewhere in any form without written permission.

      ii. Licensing information: JOP Journals are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge & be non-commercial, they don't have to license their derivative works on the same terms.

      Published Open Access articles are distributed under this Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC). Articles can be read and shared for noncommercial purposes under the following conditions:

      BY: Attribution must be given to the original source (Attribution) NC: Works may not be used for commercial purposes (Noncommercial) JOP Journals use the CC BY-NC to protect the author's work from misuse. For more information about creative commons licences, please see: https://creativecommons.org
  • 8. Author fees
    • Neither page charge, article processing charge (also known as a publication fee) for accepted articles nor submission fee will be applied. It is the platinum open access journal.
  • 9. Process for the identification of and dealing with allegations of research misconduct
    • When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
  • 10. Publication ethics
    • i. Journal policies on authorship and contributorship: It is described at the Instructions to authors.
      ii. How the journal will handle complaints and appeals: The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals
      • Who complains or makes an appeal?: Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to the editor. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
      • Who is responsible to resolve and handle complaints and appeals?: The Editor, Editorial Board, or Editorial Office is responsible for them.
      • What may be the consequence of remedy?: It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee on Publication Ethics (COPE).
      iii. Journal policies on conflicts of interest / competing interests: It is described at the Instructions to authors.
      iv. Journal policies on data sharing and reproducibility; Open data policy: For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository after acceptance of the manuscript. Therefore, the submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data or waiver of data sharing, the authors should contact the editorial office. Clinical data sharing policy: This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://synapse.koreamed.org/Synapse/Data/PDFData/0063JKMS/jkms-32-1051.pdf). The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.
      If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
      v. Journal's policy on ethical oversight: When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, and ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). All studies involving human subjects or human data must be reviewed and approved by a responsible Institutional Review Board (IRB). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
      vi. Journal's policy on intellectual property: All published papers become the permanent property of the Korean Pharmacopuncture Institute. Copyrights of all published materials are owned by the Korean Pharmacopuncture Institute.
      vii. Journal's options for post-publication discussions and corrections: The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through erratum, corrigenda, or retraction.
  • 11. Publishing schedule
    • It is to be published quarterly. Supplement issues may be published.
  • 12. Access
    • This is an open-access journal distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative (CC BY-NC) license, which is for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s).
  • 13. Archiving
  • 14. Revenue sources
    • Revenue sources of journal are from the support of publisher (Korean Pharmacopuncture Institute), Korea Government’s support, and advertising rates.
  • 15. Advertising
    • Journal of Pharmacopuncture accepts any advertisements on the following basis:

      Eligibility of the advertised products or services
      All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
      - Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
      - We reserve the right to decline or cancel any advertisement at any time.
      - Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.

      Orders
      Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisements will be discussed by the editorial board and will be ultimately approved by the publisher.

      Advertisement fee
      For one print copy issue, the advertisement price for one whole page is USD 1,000 (or KRW 1,000,000). If the advertisement is half a page, the price is reduced by half. For a quarter of the page, this price is reduced by one quarter.

      Disclaimer Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
      Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
      Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.
  • 16. Direct marketing
    • Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.

Journal Info

JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
June, 2020
Vol.23 No.2

pISSN 2093-6966
eISSN 2234-6856
Quarterly

Archives >

Editorial Office

Fax
Fax +82-2-2658-9136

Most Read / Downloaded

  • Systematic Review2020-06-30

    Bee Venom Acupuncture for Shoulder Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Lei Shen1,†, Jong Ha Lee2,†, Jong Cheon Joo1, Soo Jung Park3,*, and Yung Sun Song4,*
    J Pharmacopuncture 2020; 23(2): 44-53 https://doi.org/10.3831/KPI.2020.23.008

    Abstract : ObjectivesOur review aimed to summarize and evaluate evidence on the effectiveness of bee venom acupuncture (BVA) in the treatment of shoulder pain.MethodsRandomized controlled trials (RCTs) evaluating the effectiveness of BVA on shoulder pain were searched up to October 2019 in 11 electronic databases (Medline, Embase, CENTRAL, CiNii, CNKI, VIP, Wanfang, Kmbase, NDSL, RISS, OASIS). The methodological quality of the included RCTs were evaluated using Cochrane Risk of Bias tool and a meta-analysis was performed.ResultsSeven studies were included in the review, and four studies were included in the meta-analysis. Comparing BVA plus conventional therapy (CT) with saline injection plus CT, it showed an effect in favor of BVA plus CT in visual analog scale (VAS) and pain rating scale (PRS) (p = 0.02, p = 0.009, respectively). Comparing BVA plus physiotherapy (PT) with saline injection plus PT, it showed that there was no significant difference in VAS and verbal rating scale (VRS) between the two groups.ConclusionThis systematic review and meta-analysis suggest that BVA could be beneficial as an adjuvant treatment for shoulder pain.

    Abstract
  • Review Article2020-06-30

    Current and Future molecular mechanism in Inflammation and Arthritis

    Vikash Sharma1, Raj Kumar Tiwari1, Shiv Shankar Shukla1, and Ravindra Kumar Pandey1,*
    J Pharmacopuncture 2020; 23(2): 54-61 https://doi.org/10.3831/KPI.2020.23.009

    Abstract : Inflammation is an immune response of the human body but excessive inflammation is taken as a major factor in the development of many diseases including autoimmune disorders, cancer and nerve disorders etc. In this regards the need is to suppress the inflammatory response. Suppression of extra or imperfect inflammatory response is not a big deal provided there is an exact knowledge of particular target in the body. Recent advancements in Pharmacological aspect made the therapy with improved outcomes in number of patients. Anticytokine therapy might be one of the important and novel approaches for inflammation and Arthritis. This can be achieved only when we go through the pathophysiology of expression and identification of mediators. Let’s take an example of cytokine like interleukins (IL), chemokines, interferons (INF), tumor necrosis factors (TNF-α), growth factors, and colony stimulating factors) release pathway which is a major signalling protein in inflammatory response. In the present study we have reviewed the recent pharmacological therapeutic advancement, inflammatory mediators, receptors, and major signalling pathways. Such information will not only provide the idea about the mechanism of action of Pharmaceuticals and molecular targets but also it provides a new aspect for drug designing and new corrective approaches in existing clinical medicines. This study will be a source of good information for the researchers working in the area of drug designing and molecular Pharmacology especially in anti-inflammatory and anti arthritic medicines for target based therapy.

    Abstract
  • Review Article2020-03-31

    Nicotine Addiction: Neurobiology and Mechanism

    Raj Kumar Tiwari1, Vikas Sharma1, Ravindra Kumar Pandey2, and Shiv Shankar Shukla2,*
    J Pharmacopuncture 2020; 23(1): 1-7 https://doi.org/10.3831/KPI.2020.23.001

    Abstract : Nicotine, primary component of tobaco produces craving and withdrawal effect both in humans and animals. Nicotine shows a close resemblance to other addictive drugs in molecular, neuroanatomical and pharmacological, particularly the drugs which enhances the cognitive functions. Nicotine mainly shows its action through specific nicotinic acetylcholine receptors located in brain. It stimulates presynaptic acetylcholine receptors thereby enhancing Ach release and metabolism. Dopaminergic system is also stimulated by it, thus increasing the concentration of dopamine in nuclear accumbens. This property of nicotine according to various researchers is responsible for reinforcing behavioral change and dependence of nicotine. Various researchers have also depicted that some non dopaminergic systems are also involved for rewarding effect of nicotinic withdrawal.Neurological systems such as GABAergic, serotonergic, noradrenergic, and brain stem cholinergic may also be involved to mediate the actions of nicotine. Further, the neurobiological pathway to nicotine dependence might perhaps be appropriate to the attachment of nicotine to nicotinic acetylcholine receptors, peruse by stimulation of dopaminergic system and activation of general pharmacological changes that might be responsible for nicotine addiction. It is also suggested that MAO A and B both are restrained by nicotine. This enzyme helps in degradation dopamine, which is mainly responsible for nicotinic actions and dependence. Various questions remain uninsurable to nicotine mechanism and require more research. Also, various genetic methods united with modern instrumental analysis might result for more authentic information for nicotine addiction.

    Abstract
All Newest Articles
  • Original Article2019-10-01

    Evaluation of the Single-Dose Toxicity of TA Pharmacopuncture in Rats

    Ji Hye Hwang1,*, Hyo Won Jung2, and Chul Jung3,*
    J Pharmacopuncture 2019; 22(3): 171-175 https://doi.org/10.3831/KPI.2019.22.023

    Abstract : ObjectivesTA is a polyherbal extract comprising seven herbs, typically used for the pharmacopuncture treatment of patients with traffic accident-related injuries and musculoskeletal diseases. This animal study was conducted to evaluate the safety of the TA extract, using a single-dose toxicity test.MethodsThe dose range and sampling time were first established. Six-week-old Sprague–Dawley rats were administered 1.0 mL of TA or normal saline (control), intramuscularly, for the single-dose toxicity test. The general condition, mortality, and histology of all rats were observed for 2 weeks.ResultsNo abnormal symptoms or deaths were observed in any group. The body weights of the rats in the TA and control groups were similar. No significant differences in histopathology were observed between the groups.ConclusionOur study indicates that 1.0 mL of TA extract may be safely administered for pharmacopuncture for treatment of patients in traditional medicine clinics.

    Abstract
  • Opinions2020-06-30
  • Review Article2020-06-30

    Current and Future molecular mechanism in Inflammation and Arthritis

    Vikash Sharma1, Raj Kumar Tiwari1, Shiv Shankar Shukla1, and Ravindra Kumar Pandey1,*
    J Pharmacopuncture 2020; 23(2): 54-61 https://doi.org/10.3831/KPI.2020.23.009

    Abstract : Inflammation is an immune response of the human body but excessive inflammation is taken as a major factor in the development of many diseases including autoimmune disorders, cancer and nerve disorders etc. In this regards the need is to suppress the inflammatory response. Suppression of extra or imperfect inflammatory response is not a big deal provided there is an exact knowledge of particular target in the body. Recent advancements in Pharmacological aspect made the therapy with improved outcomes in number of patients. Anticytokine therapy might be one of the important and novel approaches for inflammation and Arthritis. This can be achieved only when we go through the pathophysiology of expression and identification of mediators. Let’s take an example of cytokine like interleukins (IL), chemokines, interferons (INF), tumor necrosis factors (TNF-α), growth factors, and colony stimulating factors) release pathway which is a major signalling protein in inflammatory response. In the present study we have reviewed the recent pharmacological therapeutic advancement, inflammatory mediators, receptors, and major signalling pathways. Such information will not only provide the idea about the mechanism of action of Pharmaceuticals and molecular targets but also it provides a new aspect for drug designing and new corrective approaches in existing clinical medicines. This study will be a source of good information for the researchers working in the area of drug designing and molecular Pharmacology especially in anti-inflammatory and anti arthritic medicines for target based therapy.

    Abstract
All Newest Articles

Scimago Journal & Country Rank

SCImago Journal & Country Rank